Zacks Research Issues Pessimistic Outlook for BAX Earnings

Baxter International Inc. (NYSE:BAX) – Research analysts at Zacks Research decreased their Q1 2025 earnings estimates for shares of Baxter International in a research report issued on Thursday, March 13th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will earn $0.49 per share for the quarter, down from their previous forecast of $0.50. The consensus estimate for Baxter International’s current full-year earnings is $2.48 per share. Zacks Research also issued estimates for Baxter International’s Q2 2025 earnings at $0.60 EPS, Q3 2025 earnings at $0.66 EPS, Q1 2026 earnings at $0.52 EPS, Q2 2026 earnings at $0.65 EPS, Q3 2026 earnings at $0.73 EPS, FY2026 earnings at $2.63 EPS and FY2027 earnings at $2.82 EPS.

Baxter International (NYSE:BAX) last released its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.52 by $0.06. The firm had revenue of $2.75 billion for the quarter, compared to analysts’ expectations of $2.67 billion. Baxter International had a negative net margin of 5.05% and a positive return on equity of 16.67%.

Several other research analysts have also recently commented on the stock. Barclays raised their target price on shares of Baxter International from $39.00 to $41.00 and gave the stock an “overweight” rating in a report on Monday, March 10th. Citigroup lowered their target price on shares of Baxter International from $37.00 to $35.00 and set a “neutral” rating on the stock in a report on Wednesday, December 11th. Argus raised shares of Baxter International from a “hold” rating to a “buy” rating in a report on Monday, February 24th. JPMorgan Chase & Co. lowered their target price on shares of Baxter International from $38.00 to $36.00 and set a “neutral” rating on the stock in a report on Friday, February 21st. Finally, The Goldman Sachs Group assumed coverage on shares of Baxter International in a report on Wednesday, February 26th. They set a “buy” rating and a $42.00 target price on the stock. One analyst has rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $38.56.

Baxter International Stock Up 0.7 %

Baxter International stock opened at $34.85 on Monday. Baxter International has a twelve month low of $28.34 and a twelve month high of $43.99. The company’s 50-day moving average price is $32.57 and its two-hundred day moving average price is $33.93. The stock has a market cap of $17.83 billion, a P/E ratio of -27.22, a P/E/G ratio of 0.93 and a beta of 0.60. The company has a quick ratio of 1.09, a current ratio of 1.43 and a debt-to-equity ratio of 1.31.

Institutional Trading of Baxter International

Large investors have recently made changes to their positions in the company. CoreFirst Bank & Trust acquired a new stake in shares of Baxter International during the 4th quarter worth approximately $26,000. Riverview Trust Co boosted its position in Baxter International by 5,488.2% in the fourth quarter. Riverview Trust Co now owns 950 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 933 shares in the last quarter. LRI Investments LLC boosted its position in Baxter International by 60.8% in the third quarter. LRI Investments LLC now owns 1,560 shares of the medical instruments supplier’s stock valued at $59,000 after buying an additional 590 shares in the last quarter. Bruce G. Allen Investments LLC boosted its position in Baxter International by 247.3% in the fourth quarter. Bruce G. Allen Investments LLC now owns 2,622 shares of the medical instruments supplier’s stock valued at $76,000 after buying an additional 1,867 shares in the last quarter. Finally, CKW Financial Group boosted its position in Baxter International by 19.3% in the fourth quarter. CKW Financial Group now owns 2,625 shares of the medical instruments supplier’s stock valued at $77,000 after buying an additional 425 shares in the last quarter. Institutional investors and hedge funds own 90.19% of the company’s stock.

Baxter International Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Friday, February 28th will be given a dividend of $0.17 per share. The ex-dividend date of this dividend is Friday, February 28th. This represents a $0.68 annualized dividend and a dividend yield of 1.95%. Baxter International’s dividend payout ratio is -53.13%.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.